Pharmadiet, the Spain subsidiary of OPKO Health, has obtained Spanish approval for commercialization of its oral and injectable formulations of citicoline, developed to enhance phosphatidylcholine levels in the brain.
Agencia Espa ola de Medicamentos y Productos Sanitarios, Spain's health authority, approved the product while final marketing authorization is expected within 60 to 90 days.
OPKO chairman and chief executive officer Phillip Frost said, "OPKO plans to commercialize its oral and injectable citicoline products in Europe, Latin America, and other markets as well."
Citicoline formulations are indicated to treat memory disorders and behavior related to stroke, head injury, chronic disease, in addition to degenerative brain disorders.
